Article
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Molecular oncology - 1 Jun 2017
Kudo Kenichiro, Ohashi Kadoaki, Makimoto Go, Higo Hisao, Kato Yuka, Kayatani Hiroe, Kurata Yasuko, Takami Yoichiro, Minami Daisuke, Ninomiya Takashi, Kubo Toshio, Ichihara Eiki, Sato Akiko, Hotta Katsuyuki, Yoshino Tadashi, Tanimoto Mitsune, Kiura Katsuyuki
Abstract excerpt
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR-mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR. Combination therapy using afatinib and cetuximab has had good results in lung tumors harboring EGFRT790M mutations in clinical trials. The effect of bevacizumab, an antivascular endothelial growth...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.